{"id":106492,"date":"2026-07-22T08:58:13","date_gmt":"2026-07-22T08:58:13","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/106492\/"},"modified":"2026-07-22T08:58:13","modified_gmt":"2026-07-22T08:58:13","slug":"swiss-pharma-firm-sandoz-takes-note-of-proposed-us-tariffs-on-generic-drugs","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/106492\/","title":{"rendered":"Swiss pharma firm Sandoz takes note of proposed US tariffs on generic drugs"},"content":{"rendered":"<p>    <img src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/07\/b776521329cd5de213d8eea7804e43a506767eff-91782198.jpg\" width=\"1400\" height=\"1050\" alt=\"Sandoz &quot;takes note&quot; of the new US tariffs\" loading=\"eager\" decoding=\"sync\" fetchpriority=\"high\"\/><\/p>\n<p>                Sandoz &#8220;takes note&#8221; of the new US tariffs            <\/p>\n<p>            Keystone-SDA        <\/p>\n<p>        Generic drugs giant Sandoz said on Wednesday that it had \u201ctaken note\u201d of Washington\u2019s announcements regarding new tariffs on this type of medication, adding that it was \u201cstill too early\u201d to assess the implications.\n<\/p>\n<p>        This content was published on    <\/p>\n<p>        July 22, 2026 &#8211; 10:15\n<\/p>\n<p>\u201cAt this stage, it is too early to assess the potential implications, as further details on the implementation and scope of this measure are still required\u201d, particularly regarding the group\u2019s geographical presence and its \u201cfuture investment decisions\u201d, said a spokesperson for the Basel-based group, when questioned by the AWP news agency.<\/p>\n<p>According to the spokesperson, Sandoz will continue \u201cto monitor developments closely and engage in constructive dialogue with the relevant stakeholders\u201d, without providing further details.<\/p>\n<p>\n    More<\/p>\n<p>    <img src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/07\/CHAIR_GHOSTINE.jpg\" width=\"1269\" height=\"846\" alt=\"portrait\" loading=\"lazy\" decoding=\"async\" fetchpriority=\"auto\"\/><\/p>\n<p>        More    <\/p>\n<p>        Medicine access\n        <\/p>\n<p>        Sandoz board chair \u2018convinced that common sense will ultimately prevail\u2019 on US pharma tariffs    <\/p>\n<p class=\"teaser-wide-card__excerpt\">\n<p>                        This content was published on                    <\/p>\n<p>                        Jun 28, 2025                    <\/p>\n<p>                In an exclusive interview with Swissinfo, Sandoz chair Gilbert Ghostine says he remains optimistic despite looming tariff hikes.            <\/p>\n<p>    <a class=\"teaser-wide-card__link\" href=\"https:\/\/www.swissinfo.ch\/eng\/medicine-access\/sandoz-board-chair-is-convinced-that-common-sense-will-ultimately-prevail-on-us-pharma-tariffs\/89580213\" target=\"_self\" rel=\"nofollow noopener\"><\/p>\n<p>            Read more: Sandoz board chair \u2018convinced that common sense will ultimately prevail\u2019 on US pharma tariffs<br \/>\n    <\/a><\/p>\n<p>US President Donald Trump announced on Tuesday that generic medicines will be subject to 100% tariffs from August 2028, a measure which, he said, aims to bring back the production of pharmaceutical products to the US.<\/p>\n<p>Up to 200%<\/p>\n<p>\u201c\u201dEffective August 1st, 2026, all generic drugs being brought into the United States will continue to have a tariff of zero percent for a two year period of time, after which the tariff will be raised to 100% for a one year period of time, and 200% thereafter,\u201d Trump wrote on his Truth Social platform.<\/p>\n<p>Generic medicines had until now been exempt from US tariffs on pharmaceutical products that were announced in April, which can reach up to 100%. The US President had, however, given his Secretary of Commerce a year to reassess the situation and recommend, if necessary, new measures on imports of generic medicines.<\/p>\n<p>\u201cThis is done in order to reshore generic pharmaceutical production into America, with a penalty to those companies that decide not to build plant and equipment within the stated period of time given to them,\u201d the Republican president explained in his message.<\/p>\n<p>He added that the measures already in force concerning other medicines would remain \u201cunchanged\u201d.<\/p>\n<p>+ <a href=\"https:\/\/www.swissinfo.ch\/eng\/about-us\/how-swissinfo-produces-news-in-english\/91695684\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">How we produce English news<\/a><br \/>Translated from German, reviewed by an\u00a0<a href=\"https:\/\/www.swissinfo.ch\/eng\/department\/english-department\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">English Department<\/a> journalist.\u00a0<\/p>\n<p>        Articles in this story    <\/p>\n","protected":false},"excerpt":{"rendered":"Sandoz &#8220;takes note&#8221; of the new US tariffs Keystone-SDA Generic drugs giant Sandoz said on Wednesday that it&hellip;\n","protected":false},"author":2,"featured_media":106493,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[101,300,114,100,103,41,17],"class_list":["post-106492","post","type-post","status-publish","format-standard","has-post-thumbnail","category-switzerland","tag-article","tag-beat-pharma-supply-chains","tag-business","tag-latest-news","tag-production-type-deepl-autotranslation","tag-swiss","tag-switzerland"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116962807519347928","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/106492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=106492"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/106492\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/106493"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=106492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=106492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=106492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}